Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | MIF | P14174 | 1/20 | 0.32 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.30 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.30 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7314143 | 0.98 | KDM4E (0.35) | LMNAHSD17B10CYP2C19KMT2AKDM4E | |
| SCHEMBL28285942 | 0.83 | ALDH1A1 (0.37) | LMNAKDM4ECYP1A2 | |
| SCHEMBL23049725 | 0.83 | LMNA (0.33) | LMNAHSD17B10KDM4ECYP1A2 | |
| SCHEMBL9325262 | 0.79 | SERPINE1 (0.32) | LMNAHSD17B10KDM4E | |
| SCHEMBL23049572 | 0.79 | LMNA (0.33) | LMNAHSD17B10KDM4E | |
| SCHEMBL722025 | 0.79 | GAA (0.50) | LMNAHSD17B10CYP2C19KMT2AMIF | |
| SCHEMBL2485813 | 0.79 | ADRA2A (0.42) | LMNAHSD17B10CYP2C19KMT2ACYP1A2 | |
| SCHEMBL7588073 | 0.79 | MAPK1 (0.37) | LMNAKDM4ECYP1A2GLRA1SLC6A9 | |
| SCHEMBL2059154 | 0.78 | MGAM (0.50) | CYP2C19KMT2AKDM4EMIF | |
| SCHEMBL20925319 | 0.78 | CYP1A2 (0.61) | LMNAHSD17B10KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113677692-A | Neurotensin agonists and methods of preventing or treating pain using the same | 健康与人类科学公司 | 2021-11-19 | — | — | CN | claimed |
| CN-113603387-A | Waterproof concrete synergist and preparation method thereof | 浙江鑫美博新材料有限公司 | 2021-11-05 | — | — | CN | claimed |
| EP-1586636-A1 | Hydantoinase variants with improved properties and their use for the production of amino acids | Degussa AG (DE) | 2005-10-19 | — | — | EP | claimed |
| EP-1165763-B1 | HYDANTOINASE VARIANTS WITH IMPROVED PROPERTIES AND THEIR USE FOR THE PRODUCTION OF AMINO ACIDS | CALIFORNIA INST OF TECHN (US) | 2005-06-22 | — | — | EP | claimed |
| WO-2005017171-A2 | PROCESS FOR THE PRODUCTION OF D-AMINO ACIDS | DEGUSSA AG (DE) | 2005-02-24 | — | — | WO | claimed |
| JP-2003521235-A | — | — | 2003-07-15 | — | — | JP | claimed |
| EP-1165763-A4 | HYDANTOINASE VARIANTS WITH IMPROVED PROPERTIES AND THEIR USE FOR THE PRODUCTION OF AMINO ACIDS | CALIFORNIA INST OF TECHN (US) | 2003-05-28 | — | — | EP | claimed |
| EP-1165763-A1 | HYDANTOINASE VARIANTS WITH IMPROVED PROPERTIES AND THEIR USE FOR THE PRODUCTION OF AMINO ACIDS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2002-01-02 | — | — | EP | claimed |
| WO-2000058449-A1 | HYDANTOINASE VARIANTS WITH IMPROVED PROPERTIES AND THEIR USE FOR THE PRODUCTION OF AMINO ACIDS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2000-10-05 | — | — | WO | claimed |
| EP-0299397-A2 | Peptides with vasorelaxing, natriuretic and diuretic activities, preparation process, agents containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-01-18 | — | — | EP | claimed |
| US-12459974-B2 | Bicyclic peptide ligands specific for Nectin-4 | BICYCLETX LIMITED (GB) | 2025-11-04 | — | — | US | disclosed |
| EP-4610269-A1 | UROKINASE PLASMINOGEN ACTIVATOR SURFACE RECEPTOR (UPAR) LIGANDS FOR DIAGNOSTIC OR THERAPEUTIC USE | 3B Pharmaceuticals GmbH (DE) | 2025-09-03 | — | — | EP | disclosed |
| US-20250263438-A9 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4 | BICYCLETX LIMITED (GB) | 2025-08-21 | — | — | US | disclosed |
| EP-4588934-A2 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4 | BicycleTX Limited (GB) | 2025-07-23 | — | — | EP | disclosed |
| CN-120152745-A | Compounds and their use for detecting diseases in exhaled breath of a subject | 奥斯通医疗有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-1200374-A | Vitronectin receptor antagonists, their preparation and use | HOECHST AG (DE) | 1998-12-02 | — | — | CN | disclosed |
| WO-1998040092-A1 | DOLASTATIN-15 DERIVATIVES IN COMBINATION WITH TAXANES | BASF AKTIENGESELLSCHAFT (DE) | 1998-09-17 | — | — | WO | disclosed |
| CN-1193022-A | Heterocyclic compound used as leucocyte adherence inhibitor and VLA-4 antagonist | HOECHST AG (DE) | 1998-09-16 | — | — | CN | disclosed |
| CN-1187490-A | 5-membered ring heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists | HOECHST AG (DE) | 1998-07-15 | — | — | CN | disclosed |
| EP-0299397-A2 | Peptides with vasorelaxing, natriuretic and diuretic activities, preparation process, agents containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459974-B2 | Bicyclic peptide ligands specific for Nectin-4 | NECTIN4, VCAM1, SIGLEC7 | LMNA 2666/4885HSD17B10 3873/4885CYP2C19 4698/4885 |
| US-20250263438-A9 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4 | NECTIN4, VCAM1, SIGLEC7 | LMNA 2666/4885HSD17B10 3873/4885CYP2C19 4698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.